Results 201 to 210 of about 94,577 (314)
Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well‐Tolerated in a Pivotal Phase III Trial
Allergy, EarlyView.A pivotal Phase III DBPC adaptive trial was conducted with PQ Grass 27600 SU. The primary endpoint EAACI‐CSMS0–6 demonstrated a highly significant, clinically meaningful improvement for PQ Grass of −0.27 points (95% CI: −0.42 to −0.12), corresponding to a relative difference of −20.3% (p = 0.0005) over placebo. Highly consistent secondary endpoints and Stefan Zielen, Jonathan A. Bernstein, Gunter J. Sturm, Marek Jutel, Oliver Pfaar, the RESONATE Investigator Group, R. Gattringer, K. Gangl, J. Potesil, T. Sykora, M. Mattauchova, P. Panzner, M. Kasl, Z. Chovancova, T. Hofstetr, J. Poloniova, A. Zlamal, J. Haas, F. Heimlich, C. Korte, S. Ballenberger, J. Grosskopf, P. Heymer, C. Bergmann, M. Froer, G. Hoheisel, U. Thieme, C. Grigat, U. Schaefer, P. El Naib, A. Schwinn, S. Runge, M. Worm, S. Pauser, M. Jandl, J.‐C. Bohn, C. von Engelhardt, A. Schaefer, J. Rieker‐Schwienbacher, M. Cuevas, S. Lassmann, Y. Yarin, T. Nyeky, I. Szanyi, V. Urban, J. Nemes, P. Borowy, Z. Siergiejko, E. Janusik, B. Tluczykont, D. Madra‐Rogacka, S. Ptaczek, I. Wojciechowska, J. Orlicz‐Widawska, M. Żurowska‐Gębala, T. Hofman, S. Tokarski, M. Bederska, A. Latos, K. Kowal, E. Markut‐Miotla, E. Pisarczyk‐Bogacka, P. Kuna, B. Majorek‐Olechowska, A. Chmielewska, B. Kucinska, C. Chwala, P. Parikh, J. Sublett, J. Weiss, J. Leflein, P. Shapero, D. McNeil, K. O’Brien, E. Sher, G. Steven, L. Ford, A. Darter, L. Clore, D. Elkayam, G. Myers, J. Matz, M. Vanderwalker, S. Smiley, J. DeAngelo, A. Montanaro, J. Delgado, W. Greisner, C. Thornblade, M. Moss, Mohamed H. Shamji, Ralph Mösges, Markus Berger, Uwe E. Berger, Lawrence DuBuske, Janice A. Layhadi, Ludger Klimek, Markus Ollert, Murray A. Skinner, Matthias F. Kramer, Pieter‐Jan de Kam +100 morewiley +1 more sourceSystemic reactions to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis and/or asthma: A real‐life, multi‐center study
Allergy, EarlyView.Qingxiu Xu, Jiaxin Jia, Hang Lin, Dan Liang, Hao Chen, Yin Wang, Xiang Gao, Wang Liao, Guohua Chen, Lihong Yang, Qianlan Zhou, Jun Bai, Zhihai Xie, Lishen Shan, Rongfei Zhu +14 morewiley +1 more sourceOral Immunotherapy in Peanut‐Allergic Adults Using Real‐World Materials
Allergy, EarlyView.In 21 adults initiated on peanut oral immunotherapy (OIT), 67% tolerated at least 1000 mg on exit DBPCFC. Decreases in SPT size and increases in peanut‐ and Ara h 2‐specific IgG occurred in OIT participants but not in mechanistic controls (n = 9). Improvements were seen in FAQLQ‐AF and food neophobia scores.Hannah Hunter, Kok Loong Ue, Victoria Cornelius, Ching Ching Yung, Iason Thomas, Olympia Tsilochristou, Janice Layhadi, Leonard Q. C. Siew, Carina Venter, Mohamed H. Shamji, Stephen J. Till +10 morewiley +1 more source
